阿罗格标准化尘螨疫苗治疗变应性鼻炎的疗效和安全性

Effect and safety analysis of Allergovit standardized mite allergen immunotherapy in patients with allergic rhinitis

目的：探讨标准化皮下特异性免疫治疗（SCIT）变应性鼻炎（AR）的临床疗效和安全性。方法：收集2006-01-2009—01应用阿罗格尘螨疫苗进行3年标准化SCIT并有完整随访资料的425例AR患者的资料进行回顾性分析，其共完成31088次尘螨变应原疫苗注射。通过比较治疗前后患者的生活质量评分，治疗前及免疫治疗后每6周记录的鼻症状VAS评分及药物评分，评估该疗法的临床疗效。分析剂量递增期和剂量维持期的局部及全身不良反应的发生情况，评估疗法的安全性。结果：免疫治疗前总体生活质量评分[中位数（25分位数；75分位数），下同]为3．8（2．9；4．5）分，3年免疫治疗后为1．1（1．0；2．0）分，差异有统计学意义（P〈0．01）；治疗前鼻部症状VAS评分（0～40分）及药物评分分别为23．7（20．5；27．8）分及3．9（3．2；4．7）分，治疗后分别为2．1（1．6；2．2）分及0（0；0）分，差异有统计学意义（均P〈0．01）。在剂量维持阶段，患者的症状及药物评分基本稳定．局部不良反应发生率为3．15％，全身不良反应发生率为0．90％。结论：SCIT是治疗尘螨引起AR的一种安全、有效的治疗方法。

Objective：To evaluate the effect and safety analysis of Allergovit standardized dust mite subcutane- ous immunotherapy in patients with allergic rhinitis. Method：From Jan 2006 to Jan 2009,425 patients with persis- tent were treated with Allergovit standardized dust mite allergen in 3 years, which data were retrospectively ana lyzed. The scores of the rhinoconjunctivitis quality of life were collected per-treatment and three years treatment. VAS（visual analogue scale）of all nasal symptoms and drug use scores were evaluated before treatment and every 6 weeks. The frequency of local and systemic reactions were recorded in the duration of dose escalation and mainte nance. Result：The Overall QOI. were significantly improved after 3 years treatment[pre-treatment：3.8 （2.9;4.5） ; post-treatment： 1.1 （1.0;2.0）,P〈0.01]. VAS of all nasal symptoms and drug used scores decreased dramatically after escalation periodVpro-treatment ： 23.7 （ 20.5 ; 27.8）, 3.9 （ 3.2 ; 4.7 ） ; post-treatment： 2.1 （ 1.6 ; 2.2 ）, 0 （ 0 ; 0 ）, P〈0. 01]. Local reaction＇s rate was 3. 15%, the frequency systemic reaction＇s rate was 0. 90%. Conclusion： The standardized specific allergen immunotherapy for allergic rbinitis is safe and effective.